HPLC-MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-16. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
==== B. Aesthetics of the nose – nasal subunits and nasal segments ==== To plan, map, and execute the surgical correction of a nasal defect or deformity, the structure of the external nose is divided into nine aesthetic nasal subunits, and six aesthetic nasal segments, which provide the plastic surgeon with the measures for determining the size, extent, and topographic locale of the nasal defect or deformity.
2-hydroxyisoflavanone synthase (EC 1.14.14.87, CYT93C, IFS, isoflavonoid synthase) is an enzyme with systematic name liquiritigenin,NADPH:oxygen oxidoreductase (hydroxylating, aryl migration). It catalyses a rearrangement reaction which converts flavonoids into isoflavones, for example:
Catalytic efficiency: Fusion of certain peptides allow for greater catalytic efficiency by altering the tertiary and quaternary structure of the target protein. Solubility: A common challenge in fusion protein design is the issue of insolubility of newly synthesized fusion proteins in the recombinant host, leading to an over-aggregation of the target protein in the cell. Molecular chaperones that are able to aid in protein folding may be added, thereby better segregating hydrophobic and hydrophilic interactions in the solute to increase protein solubility. Thermostability: Singular peptides or protein fragments are typically added to reduce flexibility of either the N or C terminus of the target protein, which reinforces thermostability and stabilizes pH range. Enzyme activity: Fusion that involves the introduction of hydrogen bonds may be used to expand overall enzyme activity. Expression levels: Addition of numerous fusion fragments, such as maltose binding protein (MBP) or small ubiquitin-like molecule (SUMO), serve to enhance enzyme expression and secretion of the target protein. Immobilization: PHA synthase, an enzyme that allows for the immobilization of proteins of interest, is an important fusion tag in industrial research. Crystal quality: Crystal quality can be improved by adding covalent links between proteins, aiding in structure determination techniques.
Based on a precautionary approach, WHO recommends focusing control of exposure on preventing inhalation exposure with the aim of reducing it as much as possible (strong recommendation, moderate-quality evidence). WHO recommends reduction of exposures to a range of MNMs that have been consistently measured in workplaces especially during cleaning and maintenance, collecting material from reaction vessels and feeding MNMs into the production process. In the absence of toxicological information, WHO recommends implementing the highest level of controls to prevent workers from any exposure. When more information is available, WHO recommends taking a more tailored approach (strong recommendation, moderate-quality evidence). WHO recommends taking control measures based on the principle of hierarchy of controls, meaning that the first control measure should be to eliminate the source of exposure before implementing control measures that are more dependent on worker involvement, with PPE being used only as a last resort. According to this principle, engineering controls should be used when there is a high level of inhalation exposure or when there is no, or very little, toxicological information available. In the absence of appropriate engineering controls PPE should be used, especially respiratory protection, as part of a respiratory protection programme that includes fit-testing (strong recommendation, moderate-quality evidence).
Sources: en.wikipedia.org
The pericardium is the sac that surrounds the heart. The tough outer surface of the pericardium is called the fibrous membrane. This is lined by a double inner membrane called the serous membrane that produces pericardial fluid to lubricate the surface of the heart. The part of the serous membrane attached to the fibrous membrane is called the parietal pericardium, while the part of the serous membrane attached to the heart is known as the visceral pericardium. The pericardium is present in order to lubricate its movement against other structures within the chest, to keep the heart's position stabilised within the chest, and to protect the heart from infection.
==== Dendrotoxins ==== Dendrotoxins inhibit neurotransmissions by blocking the exchange of positive and negative ions across the neuronal membrane lead to no nerve impulse, thereby paralyzing the nerves. Snake example: mambas
== Mechanism of action == Generally, a proportion of immature thymus-derived lymphocytes differentiate into mature CD4+ T-cells which produce a certain amount of cytokines, such as interleukin-2 (IL-2) and gamma interferon. To attack tumor cells and viruses, CD-4 cells coordinate the overall immune response and help activate CD8 T-lymphocytes. Often called “effector” or “cytotoxic” T-cells, CD-8+ T-lymphocytes they respond to intracellular pathogens and cancer cells. Under viral attack CD-4+ T-cells fail to mature, fail to produce IL-2 and gamma interferon, and consequently fail to coordinate CD-8 responses to viruses. LTCI increases the production of CD-4+ T-cells and can subsequently overcome this immunosuppression.
==== Distribution ==== In terms of distribution, it is estimated that only about 1 to 1.5% of the drug reaches the brain both in animals and humans. Following a typical 100 μg dose in humans, this would be about 1 μg that is distributed into the brain. LSD levels in different brain areas have been found to vary in monkeys. Levels were equal in blood, cerebral cortex, cerebellum, and brainstem, whereas levels were 1.5 times higher in the thalamus and extrapyramidal system, 2 to 3 times higher in the hypothalamus and limbic system, 2 to 5 times higher in the auditory and visual cortex, 5 to 7 times higher in the posterior pituitary and pineal gland, and 10 times higher in the anterior pituitary gland. These varying concentrations in different brain areas may explain the specific profile or balance of psychedelic effects of LSD. Bodily distribution of LSD has also been studied. It has been said that there is a peculiar 40-minute lag before onset of the psychedelic effects of LSD when it is administered intravenously. This has been said to be related to time-dependent interactions of LSD with the serotonin 5-HT2A receptor. However, contradicting the preceding claims, other sources have stated that intravenous injection of LSD results in onset of effects within a few minutes. In a 2025 pharmacokinetic study comparing oral and intravenous LSD, the onset orally was about 45 minutes and the onset by intravenous injection was about 2.5 minutes. In addition, intrathecal injection (intraspinal injection) is reported to have a virtually instantaneous onset of action.
CDMT can be prepared from cyanuric chloride in a mixture of methanol, water and sodium bicarbonate. CDMT directly precipitates from this aqueous reaction mixture, but careful control of base stoichiometry and temperature is required to obtain high selectivity between the mono-, di- and trimethoxy-triazines and prepare CDMT in high yield. DMTMM is prepared in a nucleophilic aromatic substitution between CDMT and NMM.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.